What Would You Change About the EOM?

Constructive advice on improving the Enhancing Oncology Model (EOM) from our expert panel.

Moderator Stuart Staggs, MSIE, senior director, strategic programs, The US Oncology Network, invites the panelists to discuss one element of the Enhancing Oncology Model (EOM) they would change, and why. Kashyap Patel, MD, CEO, Carolina Blood and Cancer Care Associates and COA president, called for CMS to include a factor to recognize the effects of COVID long haulers on total cost of care. Fred Divers, MD, chief medical officer, American Oncology Network and medical oncologist, Genesis Cancer and Blood Institute of Arkansas, returned to the MEOS payments and suggested either making them higher or creating an add-on payment to reward data collection. And Stephen Schleicher, MD, MBA, chief medical officer, Tennessee Oncology, agreed with higher MEOS payments to attract new participants but also called for a system that doesn't punish practices that prescribe newly approved, high cost drugs if they are right for the patient.

Related Videos
Davey B. Daniel, MD, Chief Medical Officer, OneOncology
Related Content
© 2023 MJH Life Sciences
All rights reserved.